CVS Health Forecast, price target & analysts
CVS Health Target price 2026 - Analyst rating & recommendation
CVS Health Classifications & Recommendation
CVS Health Price Target
| Target Price | $115.26 |
| Price | $86.46 |
| Potential |
33.31%
register free of charge
|
| Number of Estimates | 28 |
|
28 Analysts have issued a price target CVS Health 2027 .
The average CVS Health target price is $115.26.
This is
33.31%
register free of charge
$131.25
51.80%
register free of charge
$79.79
7.71%
register free of charge
|
|
| A rating was issued by 33 analysts: 28 Analysts recommend CVS Health to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the CVS Health stock has an average upside potential 2027 of
33.31%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 402.07 | 421.74 |
| 7.85% | 4.89% | |
| Net Margin | 0.44% | 2.46% |
| 64.47% | 459.44% |
29 Analysts have issued a sales forecast CVS Health 2026 . The average CVS Health sales estimate is
This results in the following potential growth metrics:
30 CVS Health Analysts have issued a net profit forecast 2026. The average CVS Health net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.39 | 8.12 |
| 62.02% | 484.17% | |
| P/E | 10.64 | |
| EV/Sales | 0.37 |
30 Analysts have issued a CVS Health forecast for earnings per share. The average CVS Health EPS is
This results in the following potential growth metrics and future valuations:
Current CVS Health Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Locked
➜
Locked
|
Locked | Sep 03 2026 |
| Argus Research |
Locked
➜
Locked
|
Locked | Aug 19 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Jul 24 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
UBS:
Locked
➜
Locked
|
Sep 03 2026 |
|
Locked
Argus Research:
Locked
➜
Locked
|
Aug 19 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Jul 24 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
